a mechanism for lifelong persistence of HIV-1, even in patients on effective 661
combination therapy. Nat Med 5:512-517. 662
7. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, 663
Gange SJ, Siliciano RF. 2003. Long-term follow-up studies confirm the stability of 664
the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727-728. 665
8. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. 1998. Early 666
establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV- 667
1 infection. Proc Natl Acad Sci U S A 95:8869-8873. 668
9. Friedman J, Cho WK, Chu CK, Keedy KS, Archin NM, Margolis DM, Karn J. 669
2011. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase 670
enhancer of Zeste 2. J Virol 85:9078-9089. 671
10. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. 2006. 672
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of 673
transcriptional initiation. Embo J 25:139-149. 674
11. Verdin E, Paras P, Jr., Van Lint C. 1993. Chromatin disruption in the promoter of 675
human immunodeficiency virus type 1 during transcriptional activation. EMBO J 676
12:3249-3259. 677
12. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. 2009. Epigenetic 678
regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 5:e1000495. 679
13. He G, Margolis DM. 2002. Counterregulation of chromatin deacetylation and histone 680
deacetylase occupancy at the integrated promoter of human immunodeficiency virus 681
type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol 682
22:2965-2973. 683
14. Karn J. 2011. The molecular biology of HIV latency: breaking and restoring the Tat- 684
dependent transcriptional circuit. Curr Opin HIV AIDS 6:4-11. 685
15. Ganesh L, Burstein E, Guha-Niyogi A, Louder MK, Mascola JR, Klomp LW, 686
Wijmenga C, Duckett CS, Nabel GJ. 2003. The gene product Murr1 restricts HIV-1 687
replication in resting CD4+ lymphocytes. Nature 426:853-857. 688
on January 26, 2017 by UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://jvi.asm.org/
32
16. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. 1995. 689
Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. 690
Genes Dev 9:2723-2735.
691
17. Nabel G, Baltimore D. 1987. An inducible transcription factor activates expression of 692
human immunodeficiency virus in T cells. Nature 326:711-713. 693
18. Budhiraja S, Famiglietti M, Bosque A, Planelles V, Rice AP. 2013. Cyclin T1 and 694
CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 695
latency in primary resting memory CD4+ T cells. J Virol 87:1211-1220. 696
19. Zhou Q, Yik JH. 2006. The Yin and Yang of P-TEFb regulation: implications for 697
human immunodeficiency virus gene expression and global control of cell growth and 698
differentiation. Microbiol Mol Biol Rev 70:646-659. 699
20. Tyagi M, Pearson RJ, Karn J. 2010. Establishment of HIV latency in primary CD4+ 700
cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 701
84:6425-6437. 702
21. Chiang K, Sung TL, Rice AP. 2012. Regulation of cyclin T1 and HIV-1 Replication 703
by microRNAs in resting CD4+ T lymphocytes. J Virol 86:3244-3252. 704
22. Hoque M, Shamanna RA, Guan D, Pe'ery T, Mathews MB. 2011. HIV-1 replication 705
and latency are regulated by translational control of cyclin T1. J Mol Biol 410:917- 706
932. 707
23. Dar RD, Hosmane NN, Arkin MR, Siliciano RF, Weinberger LS. 2014. Screening 708
for noise in gene expression identifies drug synergies. Science 344:1392-1396. 709
24. Deeks SG. 2012. HIV: Shock and kill. Nature 487:439-440. 710
25. Kulkosky J, Sullivan J, Xu Y, Souder E, Hamer DH, Pomerantz RJ. 2004. 711
Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating 712
agents. AIDS Res Hum Retroviruses 20:497-505. 713
26. Hamer DH. 2004. Can HIV be Cured? Mechanisms of HIV persistence and strategies 714
to combat it. Curr HIV Res 2:99-111. 715
27. Olesen R, Vigano S, Rasmussen TA, Sogaard OS, Ouyang Z, Buzon M, 716
Bashirova A, Carrington M, Palmer S, Brinkmann CR, Yu XG, Ostergaard L, 717
Tolstrup M, Lichterfeld M. 2015. Innate Immune Activity Correlates with CD4 T Cell- 718
Associated HIV-1 DNA Decline during Latency-Reversing Treatment with 719
Panobinostat. J Virol 89:10176-10189. 720
28. Wren LH, Stratov I, Kent SJ, Parsons MS. 2013. Obstacles to ideal anti-HIV 721
antibody-dependent cellular cytotoxicity responses. Vaccine 31:5506-5517. 722
29. Lee WS, Parsons MS, Kent SJ, Lichtfuss M. 2015. Can HIV-1-Specific ADCC 723
Assist the Clearance of Reactivated Latently Infected Cells? Front Immunol 6:265. 724
30. Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, Davey RT, Jr., 725
Dybul M, Kovacs JA, Metcalf JA, Mican JM, Berrey MM, Corey L, Lane HC, Fauci 726
AS. 1999. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells 727
in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 728
5:651-655. 729
31. Stellbrink HJ, van Lunzen J, Westby M, O'Sullivan E, Schneider C, Adam A, 730
Weitner L, Kuhlmann B, Hoffmann C, Fenske S, Aries PS, Degen O, Eggers C, 731
Petersen H, Haag F, Horst HA, Dalhoff K, Mocklinghoff C, Cammack N, Tenner- 732
Racz K, Racz P. 2002. Effects of interleukin-2 plus highly active antiretroviral therapy 733
on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 16:1479-1487. 734
32. Davey RT, Jr., Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, Natarajan V, 735
Lempicki RA, Adelsberger JW, Miller KD, Kovacs JA, Polis MA, Walker RE, 736
Falloon J, Masur H, Gee D, Baseler M, Dimitrov DS, Fauci AS, Lane HC. 1999. 737
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy 738
(HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci 739
U S A 96:15109-15114. 740
on January 26, 2017 by UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://jvi.asm.org/
33
33. Nunnari G, Leto D, Sullivan J, Xu Y, Mehlman KE, Kulkosky J, Pomerantz RJ. 741
2005. Seminal reservoirs during an HIV type 1 eradication trial. AIDS Res Hum 742
Retroviruses 21:768-775. 743
34. Lafeuillade A, Poggi C, Chadapaud S, Hittinger G, Chouraqui M, Pisapia M, 744
Delbeke E. 2001. Pilot study of a combination of highly active antiretroviral therapy 745
and cytokines to induce HIV-1 remission. J Acquir Immune Defic Syndr 26:44-55. 746
35. Levy Y, Sereti I, Tambussi G, Routy JP, Lelievre JD, Delfraissy JF, Molina JM, 747
Fischl M, Goujard C, Rodriguez B, Rouzioux C, Avettand-Fenoel V, Croughs T, 748
Beq S, Morre M, Poulin JF, Sekaly RP, Thiebaut R, Lederman MM. 2012. Effects 749
of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV- 750
infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, 751
placebo-controlled, multicenter study. Clin Infect Dis 55:291-300. 752
36. Vandergeeten C, Fromentin R, DaFonseca S, Lawani MB, Sereti I, Lederman 753
MM, Ramgopal M, Routy JP, Sekaly RP, Chomont N. 2013. Interleukin-7 promotes 754
HIV persistence during antiretroviral therapy. Blood 121:4321-4329. 755
37. Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K, Battaglia CA, 756
Landay AL, Pahwa S, Fischl MA, Asmuth DM, Tenorio AR, Altman JD, Fox L, 757
Moir S, Malaspina A, Morre M, Buffet R, Silvestri G, Lederman MM, Team AS. 758
2009. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. 759
Blood 113:6304-6314. 760
38. van Praag RM, Prins JM, Roos MT, Schellekens PT, Ten Berge IJ, Yong SL, 761
Schuitemaker H, Eerenberg AJ, Jurriaans S, de Wolf F, Fox CH, Goudsmit J, 762
Miedema F, Lange JM. 2001. OKT3 and IL-2 treatment for purging of the latent HIV- 763
1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin 764
Immunol 21:218-226. 765
39. Shen X, Xiong GL, Jing Y, Xiao H, Cui Y, Zhang YF, Shan YJ, Xing S, Yang M, 766
Liu XL, Dong B, Wang LS, Luo QL, Yu ZY, Cong YW. 2015. The protein kinase C 767
agonist prostratin induces differentiation of human myeloid leukemia cells and 768
enhances cellular differentiation by chemotherapeutic agents. Cancer Lett 356:686- 769
696. 770
40. Morgan RJ, Jr., Leong L, Chow W, Gandara D, Frankel P, Garcia A, Lenz HJ, 771
Doroshow JH. 2012. Phase II trial of bryostatin-1 in combination with cisplatin in 772
patients with recurrent or persistent epithelial ovarian cancer: a California cancer 773
consortium study. Invest New Drugs 30:723-728. 774
41. Gonelli A, Mischiati C, Guerrini R, Voltan R, Salvadori S, Zauli G. 2009. 775
Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents. Mini Rev 776
Med Chem 9:498-509.
777
42. Jiang G, Dandekar S. 2015. Targeting NF-kappaB signaling with protein kinase C 778
agonists as an emerging strategy for combating HIV latency. AIDS Res Hum 779
Retroviruses 31:4-12. 780
43. Biancotto A, Grivel JC, Gondois-Rey F, Bettendroffer L, Vigne R, Brown S, 781
Margolis LB, Hirsch I. 2004. Dual role of prostratin in inhibition of infection and 782
reactivation of human immunodeficiency virus from latency in primary blood 783
lymphocytes and lymphoid tissue. J Virol 78:10507-10515. 784
44. Brooks DG, Hamer DH, Arlen PA, Gao L, Bristol G, Kitchen CM, Berger EA, Zack 785
JA. 2003. Molecular characterization, reactivation, and depletion of latent HIV. 786
Immunity 19:413-423. 787
45. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR, 788
Pomerantz RJ. 2001. Prostratin: activation of latent HIV-1 expression suggests a 789
potential inductive adjuvant therapy for HAART. Blood 98:3006-3015. 790
46. Wolschendorf F, Duverger A, Jones J, Wagner FH, Huff J, Benjamin WH, Saag 791
MS, Niederweis M, Kutsch O. 2010. Hit-and-run stimulation: a novel concept to 792
on January 26, 2017 by UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://jvi.asm.org/
34
reactivate latent HIV-1 infection without cytokine gene induction. J Virol 84:8712- 793
8720. 794
47. Martinez-Bonet M, Clemente MI, Alvarez S, Diaz L, Garcia-Alonso D, Munoz E, 795
Moreno S, Munoz-Fernandez MA. 2015. Antiretroviral drugs do not interfere with 796
bryostatin-mediated HIV-1 latency reversal. Antiviral Res 123:163-171. 797
48. Diaz L, Martinez-Bonet M, Sanchez J, Fernandez-Pineda A, Jimenez JL, Munoz 798
E, Moreno S, Alvarez S, Munoz-Fernandez MA. 2015. Bryostatin activates HIV-1